\n\n

A phase 1/2 study of Vertex Pharmaceuticals’ investigational therapy zimislecel (VX‑880) demonstrated that all twelve participants with type 1 diabetes and impaired hypoglycemic awareness regained endogenous insulin secretion, measured by C‑peptide levels. This …

\n\n

A new, seed‑sized implant that can be injected under the skin promises to reshape how doctors manage chronic pain and certain movement disorders. Powered wirelessly from outside the body, the device does not …